Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Experimental procedure. by Nakako Okamoto (18501452)

C2GnT1 gene knock-down results in decreased binding of cells to E-selectin. by Catherine A. St. Hill (357388)

“…At a shear stress of 0.5 dynes/cm², significantly fewer C2GnT1 shRNA transduced cells accumulated on E-selectin than un-manipulated LS174T cells, *p = 0.04. …”

Pretreatment of Huh-7.5.1 cells with PF-429242 results in a dose-dependent decrease in intracellular DENV-2 NS1 protein abundance and a 3-log decrease in extracellular viral titer. by Anastasia Hyrina (3860455)

FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

“…<p>(A) HuH6 cells (2.5 x 10⁶ cells in 25% Matrigel) were injected subcutaneously into the right flank of 6-week-old female athymic nude mice. …”

A prepubertal CD decreases plasma leptin and cholesterol concentrations in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

BH₄ bioavailability was decreased in cortical and hippocampal microvessels as compared to microvessels from the cerebellum. by Susan A. Austin (768265)

Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)